Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers
Scotto L, Kinahan C, Casadei B, Mangone M, Douglass E, Murty VV, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor OA. Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes Chromosomes And Cancer 2020, 59: 639-651. PMID: 32614991, PMCID: PMC7540375, DOI: 10.1002/gcc.22884.Peer-Reviewed Original ResearchMeSH KeywordsAminopterinAntineoplastic AgentsCell Line, TumorDNA MethylationDrug Resistance, NeoplasmDual-Specificity PhosphatasesEpigenesis, GeneticHumansInhibitory Concentration 50Lymphoma, T-CellMitogen-Activated Protein Kinase PhosphatasesSTAT5 Transcription FactorConceptsDihydrofolate reductaseResistant cell linesGene expression profilesCell linesT-cell lymphoma lineAntifolate pharmacologyEpigenetic modifiersExpression analysisGene expressionExpression profilesMechanistic basisT-cell selectivityParental H9 cellsIncreases expressionT-cell lymphomaSTAT5 phosphorylationMolecular targetsGene amplificationConcentration-dependent fashionLymphoma linesH9 cellsDrug resistancePutative mechanismsCellsPutative biomarkers